Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma

Inclusion Criteria: * Diagnosis of colorectal adenoma of any grade * Age \>= 18 years. Because no dosing or adverse event (AE) data are currently available on the use of aspirin in participants \< 18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 (Karnofsky \>= 70%) * Leukocytes \>= 3,000/microliter * Absolute neutrophil count \>= 1,500/microliter * Platelets \>= 150,000/microliter * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 1.5 x institutional ULN * Creatinine =\< 1.5 x institutional ULN * Blood hemoglobin \>= 12.0 g/dL * Alkaline phosphatase =\< 1.5 x institutional ULN * Blood urea nitrogen (BUN) =\< 40 mg/dL * Estimated glomerular filtration rate (eGFR) \>= 45 mL/min * Negative fecal occult blood test * The effects of aspirin on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study phy…